Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Social media has revolutionized health-care communication across medicine, particularly in the field of oncology. In this Comment, Manochakian and Dizon highlight the role of social media in promoting patient-driven cancer research to benefit all.
In this study, Cao et al. identified previously undiscovered metabolites produced by human gut microbes that cause DNA damage, and analysed their implication for colorectal cancer development.
Schmitt et al. describe an adaptive mechanism employed by colorectal cancers to handle pro-apoptotic chemotherapeutic insults, which could represent a targetable vulnerability with combination therapy.
Two recent studies have demonstrated how senescent cancer cells alter their cell surface proteome to induce anti-tumour immune responses, highlighting the potential therapeutic role of inducing senescence to improve anti-tumour immunity.
The activation of DNA damage tolerance (DDT) pathways as part of the replication stress response to DNA damage is key for maintaining genome integrity and, as a result, these pathways are closely linked to tumorigenesis. In this Review, Cybulla and Vindigni discuss the many connections between DDT, replication stress and cancer, detail opportunities for clinical biomarker development, and outline therapeutic strategies for targeting these pathways.
This Review covers recent advances in intravital imaging of mammalian models of cancer and describes how intravital imaging can help to understand the role of the tumour microenvironment in cancer progression and metastasis, and to develop novel treatments and therapies.
In this Perspective, Wahida et al. consider six riddles in precision oncology that must be solved to achieve better clinical responses to molecular targeted therapies.